Navigation Links
Critical Pharmaceuticals Raise GBP650K
Date:11/10/2008

Investors Endorse CriticalMix Drug Delivery Technology and own Pipeline

Potential

NOTTINGHAM, England, November 10 /PRNewswire/ -- Critical Pharmaceuticals, the speciality pharmaceuticals company, today announced that it had successfully closed a third round of investment totalling GBP650,000. Based on the company's success in developing its unique CriticalMix delivery technology and matching pipeline of candidate drugs, the funding was fully supported by existing shareholders. The company has now raised in excess of GBP2 million in investment and grants since its formation in 2004 as a spin-out from Nottingham University. It also follows the recent announcement of preclinical results for a sustained release somatropin formulation, which demonstrated considerable advantages over existing once-daily products.

Lisbeth Illum, Chief Executive Officer Critical Pharmaceuticals welcomed the new round: "The new funds will be used to advance the development of our pipeline of candidate drugs and drug delivery technologies, secure and develop our intellectual property portfolio and invest in our business development capability to secure partnerships with pharmaceutical and biotechnology companies. Already we are attracting growing interest from leading names who can see the advantages of using our drug delivery technology platforms across their drug pipelines. We believe this points to an exciting future for investors and employees. We are also delighted to have attracted new investors in this round as well as the continuing and invaluable support from East Midlands Business Angels (EMBA) and the University of Nottingham who have been with us from the start."

This confidence was mirrored by one of the lead investors, Jonathan Earl, Investment Director with Catapult Venture Managers: "We believe Critical Pharmaceuticals represents an exciting opportunity. The CriticalMix drug delivery technology not only provides pharmaceutical and biotechnology companies with the opportunity to enhance their own products, but also opens the possibility of Critical developing its own pipeline of differentiated drug products. We look forward to providing support in the company's growth."

Existing investor, Nick Wright, Fund Manager of the East Midlands Early Growth Fund at E-Synergy was naturally pleased with the company's continued success: "For us, Critical Pharmaceuticals is an ideal showcase for the region's excellence in pharmaceutical services. By combining worldclass research with knowledge of the real needs of the pharmaceutical sector, Critical Pharmaceuticals has made rapid progress. We now welcome the involvement of new investors to help take the company through the next exciting stage of its development."

About Critical Pharmaceuticals

Critical Pharmaceuticals is a Nottingham UK-based biotechnology company with proprietary drug delivery technologies for the sustained release and nasal delivery of proteins and peptides and labile or insoluble small molecules. Critical Pharmaceuticals was founded by Professor Steve Howdle in 2002 based on his world leading research into supercritical fluids. Professor Howdle noticed that supercritical carbon dioxide was able to liquify certain polymers, and in a moment of inspiration realised that this could be used to encapsulate thermally labile or solvent sensitive drugs to create injectable sustained release products. As well as working in partnership with other pharmaceutical and biotechnology companies, the company is now developing a pipeline of reformulated drug candidates for areas of unmet needs including human growth hormone. For more information visit http://www.criticalpharmaceuticals.com

Corporate Inquiries

Lisbeth Illum, Chief Executive Officer

Critical Pharmaceuticals

BioCity Nottingham, NG1 1GF, UK

Tel +44-115-8820100; +44-7710-314-383

Email: lisbeth.illum@illumdavis.com


'/>"/>
SOURCE Critical Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts
2. CriticalPoint(TM) Introduces Crosswalk Tool for Sterile Compounding Regulatory Requirements
3. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference
4. RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia
5. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
6. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
8. Genetic pathway critical to disease, aging found
9. Mission critical for carbon management
10. MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 2008 UBS Healthcare Services Conference
11. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016  In ... Society of Hematology (ASH) Annual Meeting and Exposition in ... advanced biomedical engineering methods to improve the delivery of ... conditions. These new methods are designed to carry therapies ... are needed most, which could provide a substantial advantage ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma ... from the MMRF CoMMpass Study SM —the largest and ... precision medicine in multiple myeloma—will be presented at the ... Meeting & Exposition in San Diego ... to optimize treatment strategies, as well as identify pathways ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today that it will ... AC0010 at the World Conference on Lung Cancer 2016, taking place in Vienna, Austria ... I/II clinical trials for AC0010 in patients with advanced non-small cell lung cancer harboring ...
(Date:12/2/2016)... ... ... The Conference Forum has announced that the 3rd annual Immuno-Oncology 360° ... 1-3, 2017 at the Roosevelt Hotel in New York City. Led by advisors Dr ... approach, which addresses the most up-to-date information regarding business aspects, clinical advancements and scientific ...
Breaking Biology Technology:
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... , June 27, 2016 Research and ... North America 2016-2020" report to their offering. ... North America to grow at a CAGR of ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
Breaking Biology News(10 mins):